May 31, 2025
Press Releases
November 19, 2024
Panavance Announces New Discovery that Misetionamide Directly Inhibits Oncogenic Transcription Factor c-MYC
October 9, 2024
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress
August 14, 2024
Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine
February 1, 2024
Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)
November 21, 2023
International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma
October 5, 2023
Panavance to Present at the BIO Investor Forum
September 12, 2023
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer
July 5, 2023
Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series
June 29, 2023